215600.KQ
SillaJen, Inc. [215600.KQ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
215600.KQ Stock Summary
Top 10 Correlated ETFs
215600.KQ
Top 10 Correlated Stocks
215600.KQ
In the News
215600.KQ Financial details
Company Rating
-
Market Cap
466.16B
Income
-20.17B
Revenue
5.85B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
42
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-26.62
Forward P/E
-
PEG
14.8
P/S
98.39
P/B
9.49
P/C
-
P/FCF
-29.69
Quick Ratio
4.64
Current Ratio
4.87
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-196.22
EPS next Y
-
EPS next Q
-
EPS this Y
-17.17%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-34.15%
Revenue last 5Y
-15.36%
Revenue Q/Q
-56.94%
EPS Q/Q
11.63%
-
-
-
-
SMA20
14.88%
SMA50
7.77%
SMA100
27.3%
Inst Own
-
Inst Trans
-
ROA
-27%
ROE
-31%
ROC
-0.33%
Gross Margin
5%
Oper. Margin
-388%
Profit Margin
-369%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3950.0-7470.0
52W High
-55.56%
52W Low
-15.95%
RSI
61
Rel Volume
1.46
Avg Volume
984.2K
Volume
1.43M
Perf Week
6.58%
Perf Month
13.7%
Perf Quarter
44.03%
Perf Half Y
36.91%
-
-
-
-
Beta
0.56
-
-
Volatility
151.44%, 217.27%
Prev Close
-1.48%
Price
3320
Change
-3.35%
Company Profile
- Volume Average 984.2K
- Market Capitalization 466.16B
- Employee 42
- CEO Dr. Eun-Sang Moon D.D.S., DDS, M.D.
- Headquarters Seoul,KR
- IPO Date 2016-12-06
-
Website
https://www.sillajen.com 
SillaJen, Inc. engages in the development and commercialization of oncolytic immunotherapy products. The company's lead product is Pexa-Vec, which is in Phase II clinical trial for the treatment of advanced liver cancer. It also develops JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. The company was founded in 2006 and is headquartered in Seoul, South Korea.
